Loading…
Q-Line Biotech (QLINE)₹516.55−1.95%Medical Equipment & Supplies
In the Mar 2026 quarter (consolidated), Q-Line Biotech reported sales of ₹199 Cr, down 8.7% from Mar 2025, and net profit of ₹33.90 Cr, up 277.9% year on year. For the year to Mar 2026, sales were ₹343 Cr and net profit ₹55.84 Cr.
Company filings, consolidated accounts; latest reported quarter Mar 2026
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Sales | 217 | 199 |
| Expenses | 171 | 136 |
| Operating Profit | 45.03 | 62.04 |
| OPM % | 21.1% | 31.1% |
| Other Income | −10.99 | 1.99 |
| Interest | 8.01 | 11.01 |
| Depreciation | 2.99 | 6.97 |
| Profit before tax | 21.94 | 45.85 |
| Tax % | 71.0% | 26.0% |
| Exceptional items | −5.35 | −0.72 |
| Net Profit | 8.97 | 33.90 |
| EPS (Rs) | 56.05 | 21.12 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 183 | 204 | 315 | 343 |
| Expenses | 149 | 164 | 238 | 243 |
| Operating Profit | 34.04 | 38.02 | 75.05 | 98.06 |
| OPM % | 18.1% | 19.1% | 24.1% | 29.1% |
| Other Income | 1.99 | 2.99 | −7.99 | 4.99 |
| Interest | 4.01 | 6.01 | 15.02 | 19.01 |
| Depreciation | 1.99 | 3.99 | 6.98 | 10.96 |
| Profit before tax | 29.90 | 30.94 | 43.88 | 72.75 |
| Tax % | 28.0% | 29.0% | 45.0% | 23.0% |
| Exceptional items | 0.00 | 0.99 | −16.93 | −0.99 |
| Net Profit | 31.91 | 33.89 | 27.92 | 55.84 |
| EPS (Rs) | 203.72 | 218.58 | 178.34 | 34.21 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 2.01 | 2.01 | 2.01 | 16.02 |
| Reserves | 126 | 160 | 188 | 230 |
| Borrowings | 74.01 | 97.05 | 166 | 225 |
| Other Liabilities | 51.25 | 81.39 | 99.48 | 87.42 |
| Total Liabilities | 252 | 339 | 456 | 559 |
| Fixed Assets | 22.93 | 59.79 | 91.67 | 145 |
| CWIP | 12.04 | 19.05 | 63.19 | 15.05 |
| Investments | 15.96 | 28.97 | 0.00 | 16.96 |
| Other Assets | 201 | 233 | 302 | 382 |
| Inventories | 44.13 | 105 | 90.25 | 95.28 |
| Trade receivables | 32.94 | 25.97 | 82.86 | 126 |
| Cash & equivalents | 90.07 | 29.99 | 47.05 | 76.09 |
| Total Assets | 252 | 339 | 456 | 559 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from operating activity | 25.01 | −23.98 | −1.01 | 15.99 |
| Cash from investing activity | −25.93 | −44.90 | −58.89 | −28.93 |
| Cash from financing activity | 25.90 | 16.93 | 52.77 | 41.83 |
| Net cash flow | 24.95 | −51.92 | −6.98 | 28.93 |
| Capex | 29.57 | 48.77 | 56.18 | 35.82 |
| Free cash flow | −4.98 | −71.71 | −57.76 | −18.92 |
| CFO / OP % | 111.0% | −39.0% | 7.0% | 43.0% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor days | 65 | 46 | 95 | 133 |
| Inventory days | 180 | 413 | 226 | 258 |
| Days payable | 165 | 233 | 140 | 143 |
| Cash conversion cycle | 82 | 228 | 183 | 251 |
| Working capital days | −44 | 51 | 45 | 62 |
| ROCE % | — | 16.0% | 25.0% | 22.0% |
For the Mar 2026 quarter, Q-Line Biotech reported sales of ₹199 Cr, down 8.7% year on year and net profit of ₹33.90 Cr, up 277.9% year on year. The operating margin was 31.1%.
Q-Line Biotech's sales for the year to Mar 2026 were ₹343 Cr.
Net profit for the year to Mar 2026 was ₹55.84 Cr. Earnings per share over the same trailing period were ₹34.21.
Q-Line Biotech reported borrowings of ₹225 Cr at Mar 2026, against cash and equivalents of ₹76.09 Cr.
Cash from operations was ₹15.99 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹18.92 Cr.